Key facts
- It has raised $6.6M; the latest was Early Stage VC ($5.0M) in Mar 2026.
- Notable investors include GL Ventures, Hillhouse Investment Group, Baoding Venture, GRC SinoGreen Fund, Guangzhou Ruoyuchen Technology Company — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for MetaNovas AI
- ·The full record, as it builds
Funding rounds
No funding rounds for MetaNovas AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MetaNovas AI
Provider of biotechnology research services intended for scientific and medical investigation. The company encompasses assay development, medical research workflows, genetic diagnostic and therapeutic analysis capabilities, and supporting laboratory services that facilitate data generation, experimental validation, and translational study execution, enabling research organizations and clinical partners across China to accelerate discovery, improve analytical accuracy, streamline experimental design, and advance therapeutic development through integrated scientific support.
- Sector
- Healthcare
- HQ
- Shanghai, CA, China
- Founded
- 2021
- Employees
- 11
- Website
- metanovas.com/
- Ownership
- Privately Held (backing)
MetaNovas AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MetaNovas AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MetaNovas AI in its N-PORT filings yet. We sweep new filings monthly.